{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T21:48:37Z","timestamp":1775857717755,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,9,20]],"date-time":"2014-09-20T00:00:00Z","timestamp":1411171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s10620-014-3355-4","type":"journal-article","created":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T11:45:23Z","timestamp":1411127123000},"page":"195-204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Leukopenia Predicts Remission in Patients with Inflammatory Bowel Disease and Behcet\u2019s Disease on Thiopurine Maintenance"],"prefix":"10.1007","volume":"60","author":[{"given":"Mi Sung","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duk Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Jung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Pil","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Hee","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,20]]},"reference":[{"key":"3355_CR1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3109\/00365529509096316","volume":"30","author":"P Munkholm","year":"1995","unstructured":"Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn\u2019s disease patients. Scand J Gastroenterol. 1995;30:699\u2013706.","journal-title":"Scand J Gastroenterol"},{"key":"3355_CR2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00535-007-2090-4","volume":"42","author":"K Kobayashi","year":"2007","unstructured":"Kobayashi K, Ueno F, Bito S, et al. Development of consensus statements for the diagnosis and management of intestinal Behcet\u2019s disease using a modified Delphi approach. J Gastroenterol. 2007;42:737\u2013745.","journal-title":"J Gastroenterol"},{"key":"3355_CR3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/gut.4.4.299","volume":"4","author":"FC Edwards","year":"1963","unstructured":"Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut. 1963;4:299\u2013315.","journal-title":"Gut"},{"key":"3355_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-8553(01)00002-4","volume":"31","author":"EV Loftus Jr","year":"2002","unstructured":"Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:1\u201320.","journal-title":"Gastroenterol Clin North Am"},{"key":"3355_CR5","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ibd.20310","volume":"14","author":"SK Yang","year":"2008","unstructured":"Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986\u20132005: a KASID study. Inflamm Bowel Dis. 2008;14:542\u2013549.","journal-title":"Inflamm Bowel Dis"},{"key":"3355_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5009\/gnl.2010.4.1.1","volume":"4","author":"ES Kim","year":"2010","unstructured":"Kim ES, Kim WH. Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver. 2010;4:1\u201314.","journal-title":"Gut Liver"},{"key":"3355_CR7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3346\/jkms.2002.17.3.371","volume":"17","author":"HK Chang","year":"2002","unstructured":"Chang HK, Cheon KS. The clinical significance of a pathergy reaction in patients with Behcet\u2019s disease. J Korean Med Sci. 2002;17:371\u2013374.","journal-title":"J Korean Med Sci"},{"key":"3355_CR8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00054725-200207000-00002","volume":"8","author":"J Cosnes","year":"2002","unstructured":"Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn\u2019s disease. Inflamm Bowel Dis. 2002;8:244\u2013250.","journal-title":"Inflamm Bowel Dis"},{"key":"3355_CR9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10620-008-0337-4","volume":"54","author":"EC Ebert","year":"2009","unstructured":"Ebert EC. Gastrointestinal manifestations of Behcet\u2019s disease. Dig Dis Sci. 2009;54:201\u2013207.","journal-title":"Dig Dis Sci"},{"key":"3355_CR10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.7326\/0003-4819-123-2-199507150-00009","volume":"123","author":"DC Pearson","year":"1995","unstructured":"Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Internal Med. 1995;123:132\u2013142.","journal-title":"Ann Internal Med"},{"key":"3355_CR11","doi-asserted-by":"crossref","unstructured":"Timmer A, McDonald JW, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;9:CD000478.","DOI":"10.1002\/14651858.CD000478.pub3"},{"key":"3355_CR12","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/ibd.21757","volume":"18","author":"YS Jung","year":"2012","unstructured":"Jung YS, Cheon JH, Hong SP, et al. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet\u2019s disease. Inflamm Bowel Dis. 2012;18:750\u2013757.","journal-title":"Inflamm Bowel Dis"},{"key":"3355_CR13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/gut.50.4.485","volume":"50","author":"AG Fraser","year":"2002","unstructured":"Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30\u00a0year review. Gut. 2002;50:485\u2013489.","journal-title":"Gut"},{"key":"3355_CR14","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-111-8-641","volume":"111","author":"DH Present","year":"1989","unstructured":"Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641\u2013649.","journal-title":"Ann Intern Med"},{"key":"3355_CR15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/09629359891045","volume":"7","author":"AA Tanis","year":"1998","unstructured":"Tanis AA. Azathioprine in inflammatory bowel disease, a safe alternative? Mediat Inflamm. 1998;7:141\u2013144.","journal-title":"Mediat Inflamm"},{"key":"3355_CR16","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/j.1572-0241.2008.01848.x","volume":"103","author":"JP Gisbert","year":"2008","unstructured":"Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol. 2008;103:1783\u20131800.","journal-title":"Am J Gastroenterol"},{"key":"3355_CR17","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1053\/j.gastro.2006.01.048","volume":"130","author":"GR Lichtenstein","year":"2006","unstructured":"Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940\u2013987.","journal-title":"Gastroenterology"},{"key":"3355_CR18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0016-5085(98)70251-3","volume":"115","author":"BS Kirschner","year":"1998","unstructured":"Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology. 1998;115:813\u2013821.","journal-title":"Gastroenterology"},{"key":"3355_CR19","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/gast.2000.18144","volume":"119","author":"J Markowitz","year":"2000","unstructured":"Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn\u2019s disease. Gastroenterology. 2000;119:895\u2013902.","journal-title":"Gastroenterology"},{"key":"3355_CR20","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/gut.34.8.1081","volume":"34","author":"WR Connell","year":"1993","unstructured":"Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27\u00a0years of experience. Gut. 1993;34:1081\u20131085.","journal-title":"Gut"},{"key":"3355_CR21","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/gut.48.5.591","volume":"48","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. Gut. 2001;48:591\u2013592.","journal-title":"Gut"},{"key":"3355_CR22","first-page":"291","volume":"51","author":"JH Kim","year":"2008","unstructured":"Kim JH, Cheon JH, Kim WH. The frequency and the course of the adverse effects of azathioprine\/6-mercaptopurine treatment in patients with inflammatory bowel disease. Korean J Gastroenterol (Taehan Sohwagi Hakhoe chi). 2008;51:291\u2013297.","journal-title":"Korean J Gastroenterol (Taehan Sohwagi Hakhoe chi)"},{"key":"3355_CR23","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1111\/j.1572-0241.2006.00843.x","volume":"101","author":"JP Gisbert","year":"2006","unstructured":"Gisbert JP, Nino P, Rodrigo L, et al. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol. 2006;101:2769\u20132776.","journal-title":"Am J Gastroenterol"},{"key":"3355_CR24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/jhg.2009.125","volume":"55","author":"YS Jung","year":"2010","unstructured":"Jung YS, Cheon JH, Park JJ, et al. Correlation of genotypes for thiopurine methyltransferase and inosine triphosphate pyrophosphatase with long-term clinical outcomes in Korean patients with inflammatory bowel diseases during treatment with thiopurine drugs. J Hum Genet. 2010;55:121\u2013123.","journal-title":"J Hum Genet"},{"key":"3355_CR25","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1097\/MCG.0b013e3181d6baf5","volume":"44","author":"JH Kim","year":"2010","unstructured":"Kim JH, Cheon JH, Hong SS, et al. Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study. J Clin Gastroenterol. 2010;44:e242\u2013e248.","journal-title":"J Clin Gastroenterol"},{"key":"3355_CR26","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1038\/ajg.2009.331","volume":"104","author":"JH Cheon","year":"2009","unstructured":"Cheon JH, Kim ES, Shin SJ, et al. Development and validation of novel diagnostic criteria for intestinal Behcet\u2019s disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol. 2009;104:2492\u20132499.","journal-title":"Am J Gastroenterol"},{"key":"3355_CR27","doi-asserted-by":"crossref","unstructured":"Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2\u20136 (discussion 16\u201319).","DOI":"10.3109\/00365528909091339"},{"key":"3355_CR28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5217\/ir.2013.11.3.155","volume":"11","author":"HW Lee","year":"2013","unstructured":"Lee HW, Kim WH, Cheon JH. The medical treatments of intestinal Beh\u00e7et\u2019s disease: an update. Intest Res. 2013;11:155\u2013160.","journal-title":"Intest Res"},{"key":"3355_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.crohns.2007.11.001","volume":"2","author":"EF Stange","year":"2008","unstructured":"Stange EF, Travis SP, Vermeire S, et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn\u2019s Colitis. 2008;2:1\u201323.","journal-title":"J Crohn\u2019s Colitis"},{"key":"3355_CR30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10620-011-1955-9","volume":"57","author":"JJ Park","year":"2012","unstructured":"Park JJ, Cheon JH, Hong SP, et al. Outcome predictors for thiopurine maintenance therapy in patients with Crohn\u2019s disease. Dig Dis Sci. 2012;57:133\u2013141.","journal-title":"Dig Dis Sci"},{"key":"3355_CR31","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00004836-198906000-00017","volume":"11","author":"DA Burke","year":"1989","unstructured":"Burke DA, Dixon MF, Axon AT. Ulcerative colitis: prolonged remission following azathioprine-induced pancytopenia. J Clin Gastroenterol. 1989;11:327\u2013330.","journal-title":"J Clin Gastroenterol"},{"key":"3355_CR32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000329707","volume":"5","author":"YS Choi","year":"2011","unstructured":"Choi YS, Suh JP, Song KH, et al. A case of Crohn\u2019s disease with improvement after azathioprine-induced pancytopenia. Case Rep Gastroenterol. 2011;5:344\u2013349.","journal-title":"Case Rep Gastroenterol"},{"key":"3355_CR33","first-page":"362","volume":"89","author":"T Colonna","year":"1994","unstructured":"Colonna T, Korelitz BI. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn\u2019s disease. Am J Gastroenterol. 1994;89:362\u2013366.","journal-title":"Am J Gastroenterol"},{"key":"3355_CR34","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1053\/gast.1997.v113.agast971131810b","volume":"113","author":"BI Korelitz","year":"1997","unstructured":"Korelitz BI, Zlatanic J, Smith MJ, et al. Significance of WBC differential when leukopenia is induced by 6-MP for IBD. Gastroenterology. 1997;113:1810\u20131811.","journal-title":"Gastroenterology"},{"key":"3355_CR35","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1136\/gut.34.11.1535","volume":"34","author":"K Teahon","year":"1993","unstructured":"Teahon K, Bjarnason I. Comparison of leukocyte excretion and blood loss in inflammatory disease of the bowel. Gut. 1993;34:1535\u20131538.","journal-title":"Gut"},{"key":"3355_CR36","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/00042737-200109000-00013","volume":"13","author":"S Campbell","year":"2001","unstructured":"Campbell S, Ghosh S. Is neutropenia required for effective maintenance of remission during azathioprine therapy in inflammatory bowel disease? Eur J Gastroenterol Hepatol. 2001;13:1073\u20131076.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3355_CR37","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/00042737-200109000-00009","volume":"13","author":"KM Persley","year":"2001","unstructured":"Persley KM, Present DH. Neutropenia is not required for clinical remission during azathioprine therapy in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2001;13:1053\u20131055.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3355_CR38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/01.MIB.0000206544.05661.9f","volume":"12","author":"S Hande","year":"2006","unstructured":"Hande S, Wilson-Rich N, Bousvaros A, et al. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis. 2006;12:251\u2013257.","journal-title":"Inflamm Bowel Dis"},{"key":"3355_CR39","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/gut.49.5.656","volume":"49","author":"PW Lowry","year":"2001","unstructured":"Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 2001;49:656\u2013664.","journal-title":"Gut"},{"key":"3355_CR40","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1111\/j.1572-0241.1999.01532.x","volume":"94","author":"PS Kim","year":"1999","unstructured":"Kim PS, Zlatanic J, Korelitz BI, et al. Optimum duration of treatment with 6-mercaptopurine for Crohn\u2019s disease. Am J Gastroenterol. 1999;94:3254\u20133257.","journal-title":"Am J Gastroenterol"},{"key":"3355_CR41","doi-asserted-by":"crossref","unstructured":"Sahmoud T, Hoctin-Boes G, Modigliani R, et al. Identifying patients with a high risk of relapse in quiescent Crohn\u2019s disease. The GETAID Group. The Groupe d\u2019Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 1995;37:811\u2013818.","DOI":"10.1136\/gut.37.6.811"},{"key":"3355_CR42","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nri1132","volume":"3","author":"G Bouma","year":"2003","unstructured":"Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521\u2013533.","journal-title":"Nat Rev Immunol"},{"key":"3355_CR43","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1126\/science.1106442","volume":"307","author":"TT Macdonald","year":"2005","unstructured":"Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science (New York, NY). 2005;307:1920\u20131925.","journal-title":"Science (New York, NY)"},{"key":"3355_CR44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF02786467","volume":"20","author":"L Ginaldi","year":"1999","unstructured":"Ginaldi L, De Martinis M, D\u2019Ostilio A, et al. The immune system in the elderly: II. Specific cellular immunity. Immunol Res. 1999;20:109\u2013115.","journal-title":"Immunol Res"},{"key":"3355_CR45","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2036.2007.03555.x","volume":"27","author":"R D\u2019Inca","year":"2008","unstructured":"D\u2019Inca R, Bertomoro P, Mazzocco K, et al. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2008;27:166\u2013172.","journal-title":"Aliment Pharmacol Ther"},{"key":"3355_CR46","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ibd.20846","volume":"15","author":"R Horne","year":"2009","unstructured":"Horne R, Parham R, Driscoll R, et al. Patients\u2019 attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:837\u2013844.","journal-title":"Inflamm Bowel Dis"},{"key":"3355_CR47","unstructured":"Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn\u2019s disease. Cochrane Database Syst Rev. 2000:CD000067."},{"key":"3355_CR48","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s00535-003-1139-2","volume":"38","author":"T Hibi","year":"2003","unstructured":"Hibi T, Naganuma M, Kitahora T, et al. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol. 2003;38:740\u2013746.","journal-title":"J Gastroenterol"},{"key":"3355_CR49","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1586\/egh.10.59","volume":"4","author":"C Ha","year":"2010","unstructured":"Ha C, Dassopoulos T. Thiopurine therapy in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010;4:575\u2013588.","journal-title":"Expert Rev Gastroenterol Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-014-3355-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-014-3355-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-014-3355-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T11:39:22Z","timestamp":1650195562000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-014-3355-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,20]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["3355"],"URL":"https:\/\/doi.org\/10.1007\/s10620-014-3355-4","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,20]]}}}